Literature DB >> 25151541

Natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer: a phase 3, double-blind, randomized, controlled trial.

Raymond Javan Chan1, Jennifer Mann2, Lee Tripcony2, Jacqui Keller2, Robyn Cheuk2, Rae Blades2, Samantha Keogh3, Christopher Poole4, Christopher Walsh2.   

Abstract

PURPOSE: To investigate the effects of a natural oil-based emulsion containing allantoin versus aqueous cream for preventing and managing radiation-induced skin reactions. METHODS AND MATERIALS: A total of 174 patients were randomized and participated in the study. Patients received either cream 1 (the natural oil-based emulsion containing allantoin) or cream 2 (aqueous cream). Skin toxicity, pain, itching, and skin-related quality of life scores were collected for up to 4 weeks after radiation treatment.
RESULTS: Patients who received cream 1 had a significantly lower average level of Common Terminology Criteria for Adverse Events at week 3 (P<.05) but had statistically higher average levels of skin toxicity at weeks 7, 8, and 9 (all P<.001). Similar results were observed when skin toxicity was analyzed by grades. With regards to pain, patients in the cream 2 group had a significantly higher average level of worst pain (P<.05) and itching (P=.046) compared with the cream 1 group at week 3; however, these differences were not observed at other weeks. In addition, there was a strong trend for cream 2 to reduce the incidence of grade 2 or more skin toxicity in comparison with cream 1 (P=.056). Overall, more participants in the cream 1 group were required to use another topical treatment at weeks 8 (P=.049) and 9 (P=.01).
CONCLUSION: The natural oil-based emulsion containing allantoin seems to have similar effects for managing skin toxicity compared with aqueous cream up to week 5; however, it becomes significantly less effective at later weeks into the radiation treatment and beyond treatment completion (week 6 and beyond). There were no major differences in pain, itching, and skin-related quality of life. In light of these results, clinicians and patients can base their decision on costs and preferences. Overall, aqueous cream seems to be a more preferred option. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25151541     DOI: 10.1016/j.ijrobp.2014.06.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy.

Authors:  Hanxi Zhao; Wanqi Zhu; Li Jia; Xiaorong Sun; Guanxuan Chen; Xianguang Zhao; Xiaolin Li; Xiangjiao Meng; Lingling Kong; Ligang Xing; Jinming Yu
Journal:  Br J Radiol       Date:  2015-11-26       Impact factor: 3.039

Review 2.  Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review.

Authors:  Elaine Barros Ferreira; Christiane Inocêncio Vasques; Rafael Gadia; Raymond Javan Chan; Eliete Neves Silva Guerra; Luis André Mezzomo; Graziela De Luca Canto; Paula Elaine Diniz Dos Reis
Journal:  Support Care Cancer       Date:  2016-12-12       Impact factor: 3.603

3.  The Efficacy and Safety of Jaungo, a Traditional Medicinal Ointment, in Preventing Radiation Dermatitis in Patients with Breast Cancer: A Prospective, Single-Blinded, Randomized Pilot Study.

Authors:  Moonkyoo Kong; Deok-Sang Hwang; Jee Young Lee; Seong Woo Yoon
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-15       Impact factor: 2.629

4.  Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy.

Authors:  Wanqi Zhu; Li Jia; Guanxuan Chen; Hanxi Zhao; Xiaorong Sun; Xiangjiao Meng; Xianguang Zhao; Ligang Xing; Jinming Yu; Meizhu Zheng
Journal:  Oncotarget       Date:  2016-07-26

5.  Prevention of Acute Radiation-Induced Skin Reaction with NPE® Camellia Sinensis Nonfermentatum Extract in Female Breast Cancer Patients Undergoing Postoperative Radiotherapy: A Single Centre, Prospective, Open-Label Pilot Study.

Authors:  Gabriela Näf; Urs E Gasser; Hans E Holzgang; Sandra Schafroth; Christoph Oehler; Daniel R Zwahlen
Journal:  Int J Breast Cancer       Date:  2018-07-02

6.  A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients.

Authors:  Rossana Ingargiola; Maria Carmen De Santis; Nicola Alessandro Iacovelli; Nadia Facchinetti; Anna Cavallo; Eliana Ivaldi; Michela Dispinzieri; Marzia Franceschini; Carlotta Giandini; Domenico Attilio Romanello; Simona Di Biaso; Michela Sabetti; Laura Locati; Salvatore Alfieri; Paolo Bossi; Mauro Guglielmo; Fabio Macchi; Laura Lozza; Riccardo Valdagni; Carlo Fallai; Emanuele Pignoli; Ester Orlandi
Journal:  Radiat Oncol       Date:  2020-08-13       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.